Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Osman, Abdel Moneim M ^a   Bayoumi, Hadeel M ^a   Al Harthi, Sameer E ^a   Damanhouri, Zoheir A ^a   ElShal, Mohamed F ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Breast cancer cell line; Doxorubicin; Resveratrol

Indexed keywords

DOXORUBICIN; RESVERATROL; SULFORHODAMINE B;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CYTOTOXICITY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL;

EID: 84869064515     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-47     Document Type: Article

References (33)

1. Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg 2010, 8(6):448-452. 10.1016/j.ijsu.2010.05.012, 20601253.
2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992, 19(6):670-686.
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32(2):302-314. 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2, 4353012.
4. Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett 2009, 284(1):1-6. 10.1016/j.canlet.2009.01.041, 19261378.
5. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents 2003, 3(2):77-93. 10.2174/1568011033353443, 12678904.
6. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007, 224(3):274-283. 10.1016/j.taap.2006.12.025, 2083123, 17306316.
7. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A):2783-2840.
8. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112. 10.1093/jnci/82.13.1107, 2359136.
9. Van Engeland M, Nieland LJ, Ramaekerss FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31(1):1-9. 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R, 9450519.
10. Pozarowski P, Darzynkiewicz Z. Analysis of Cell Cycle by Flow Cytometry Methods. Mol.Biol 2004, 281:301-311.
11. Kitagawa S, Nabekura T, Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 2004, 56(8):1001-1005.
12. Buzadar AS, Marcus TL, Smith TL, Blumenschein GR. Early and delayed clinical cardio toxicity of doxorubicin. Cancer 1981, 55(12):2761-2765.
13. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984, 27(3):195-200. 10.1016/0033-0620(84)90004-5, 6387802.
14. Meiyanto E, Hermawan A, Junedi S, Fitriasari A, Susidarti RA. Nobile tin increased cytotoxic activity Of doxorubicin on Mcf-7 cells but not on T47d cells. IJOP 2011, 3(1):129-137.
15. Ling YH, El-Naggar AK, Priebe W, Perez-Soler R. Cell cycle dependent cytotoxicity, G2-M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized p388 cells. Mol Pharmacol 1996, 49(5):832-841.
16. Ormrod D, Holm K, Goa K, Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 1999, 15(5):389-416. 10.2165/00002512-199915050-00006, 10600046.
17. Stacey D, Hitomi M, Chen G. Infleunce of cell cycle and oncogene activity upon topoisomerase IIa expression and drug toxicity. Mol Cell Biol 2000, 20(24):9127-9130. 10.1128/MCB.20.24.9127-9137.2000, 102171, 11094065.
18. Juan ME, Vinardell MP, Planas JM. The daily oral administration of highdoses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002, 132(2):257-260.
19. Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA, Bilir A. Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 2012, 64(5):471-479. 10.1016/j.etp.2010.11.001, 21144718.
20. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22(8):1111-1117. 10.1093/carcin/22.8.1111, 11470738.
21. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and Induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7(5):1466-1473.
22. Dörrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase 9 in acute lymphoblastic leukemia cells. Cancer Res 2001, 61(12):4731-4739.
23. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P, Zappia V. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998, 250(1):53-58. 10.1006/bbrc.1998.9263, 9735330.
24. Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, Greil R, Kofler R, Csordas A. Resveratrol causes arrest in the S-phase prior to Fas independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 2000, 7(9):834-842. 10.1038/sj.cdd.4400719, 11042678.
25. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines, Clin. Cancer Res 2002, 8:893-903.
26. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, Lond 1999, 20(2):237-242.
27. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 2002, 64(9):1375-1386. 10.1016/S0006-2952(02)01296-0, 12392819.
28. Gupta SC, Kannappanm R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011, 1215:150-160. 10.1111/j.1749-6632.2010.05852.x, 3060406, 21261654.
29. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, El-Shemy HA. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011, 44(6):591-601. 10.1111/j.1365-2184.2011.00783.x, 22011009.
30. KIM HS, Kim TH. Resveratrol enhances the sensitivity of doxorubicin mediated cell proliferation, invasion, and migration in human breast cancer cell lines. 2010, http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/964.10.
31. Yang SY, Tsai SY, Hou SC, Chao PDL. Inductive modulation on Pglycoprotein and cytochrome3A by resveratrol, a constituent of grapes. Food Chemistry 2012, 133(3):683-688.
32. Chaudhary P, Roninson I. Induction of multi-drug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85(8):632-639. 10.1093/jnci/85.8.632, 8096875.
33. Herzog C, Tsokos M, Bates S, Fojo A. Increased mdr-1/P Glycoproteinexpression after treatment of human colon carcinoma cells with P Glycoprotein antagonists. J Biol Chem 1993, 268(4):2946-2952.